Table 1. Comparisons of clinical characteristics between “Treatable AD” and “Recalcitrant AD”.
Clinical parameters | Treatable AD (n=249) | Recalcitrant AD (n=32) | OR (95% CI) | P | Adjusted OR (95% CI)a | Adjusted Pa |
---|---|---|---|---|---|---|
Age (year) | 15.3±15.3 | 31.3±16.7 | ||||
Sex | ||||||
Male | 146 (58.6%) | 20 (62.5%) | Reference | - | Reference | - |
Female | 103 (41.4%) | 12 (37.5%) | 0.85 (0.39–1.79) | 0.676 | 1.05 (0.46–2.38) | 0.896 |
Onset (year) | 9.5±14.4 | 22.4±20.9 | 1.04 (1.02–1.06) | <0.001 | 0.97 (0.93–1.02) | 0.216 |
Duration (months) | 69.6±85.5 | 101.3±100.1 | 1.00 (1.00–1.01) | 0.059 | 1.00 (1.00–1.01) | 0.321 |
Type of atopic dermatitis | ||||||
Intrinsic | 47 (19.3%) | 2 (6.2%) | Reference | - | Reference | - |
Extrinsic | 197 (80.7%) | 30 (93.8%) | 3.58 (1.03–22.61) | 0.089 | 1.82 (0.48–11.87) | 0.441 |
Self-reported history of atopic diseases | 128 (51.4%) | 19 (59.4%) | 1.38 (0.66–2.98) | 0.400 | 1.80 (0.80–4.24) | 0.162 |
Self-reported family history of atopic diseases | 184 (73.9%) | 26 (81.2%) | 1.53 (0.64–4.26) | 0.370 | 12.37 (3.17–62.34) | <0.001 |
Initial EASI | 8.6±7.1 | 19.5±9.0 | 1.14 (1.09–1.19) | <0.001 | 1.13 (1.09–1.19) | <0.001 |
Associated skin findings | ||||||
Impetigo | 23 (9.2%) | 3 (9.4%) | 1.02 (0.23–3.16) | 0.980 | 1.24 (0.26–4.34) | 0.756 |
Prurigo nodularis | 31 (12.4%) | 3 (9.4%) | 0.73 (0.17–2.21) | 0.617 | 0.26 (0.06–1.13) | 0.073 |
Nummular eczema | 28 (11.2%) | 11 (34.4%) | 4.13 (1.76–9.37) | <0.001 | 2.76 (1.08–6.65) | 0.027 |
Serum IgE level (IU/mL) | ||||||
Total IgE | 573.5±859.6 | 1,384.3±1,194.7 | <0.001 | |||
<100 | 96 (38.6%) | 3 (9.4%) | Reference | - | Reference | - |
≥100, <1,000 | 110 (44.2%) | 15 (46.9%) | 4.38 (1.39–19.25) | 0.023 | 2.68 (0.80–12.22) | 0.142 |
≥1,000 | 43 (17.3%) | 14 (43.8%) | 10.42 (3.20–46.90) | <0.001 | 5.55 (1.58–25.99) | 0.013 |
Allergen-specific IgE for Dermatophagoides farinae | 179.6±975.8 | 319.3±1,064.5 | <0.001 | |||
<0.70 (0, 1+) | 139 (55.8%) | 5 (15.6%) | Reference | - | Reference | - |
≥0.70, <50.00 (2+, 3+, 4+) | 69 (27.7%) | 9 (28.1%) | 3.63 (1.21–12.19) | 0.026 | 2.15 (0.66–7.61) | 0.212 |
≥50.00 (5+, 6+) | 41 (16.5%) | 18 (56.2%) | 12.20 (4.56–38.81) | <0.001 | 11.16 (3.94–37.68) | <0.001 |
Allergen-specific IgE for Dermatophagoides pteronyssinus | 78.0±373.9 | 566.6±1,344.6 | <0.001 | |||
<0.70 (0, 1+) | 147 (59.0%) | 6 (18.8%) | Reference | - | Reference | - |
≥0.70, <50.00 (2+, 3+, 4+) | 60 (24.1%) | 6 (18.8%) | 2.45 (0.74–8.12) | 0.134 | 1.55 (0.43–5.47) | 0.492 |
≥50.00 (5+, 6+) | 42 (16.9%) | 20 (62.5%) | 11.67 (4.64–33.63) | <0.001 | 10.82 (4.04–33.71) | <0.001 |
aAdjusted by subjects' age.
AD, atopic dermatitis; OR, odds ratio; 95% CI, 95% confidential interval; EASI, Eczema Area Severity Index; IgE, immunoglobulin E.